Randox develops screening solution for parasitic disease in poultry
A “workable” solution to coccidiostats screening for the egg and poultry sector has been developed by Randox Food Diagnostics.
The company has claimed the “wait is over” for egg and poultry producers in light of its first multi-analyte screening test, which can recognise a multitude of disease control drugs.
Following 24 months of development and tests, the system aims to alleviate pressures faced by farmers dealing with coccidiostats, which is an intestinal-tract-based parasitic disease.
According to Randox, farmers are having to face ever-increasing demands for poultry meat, which, it added, leads to over-cramped conditions in sheds that can increase the chances of infection.
In order to stem infection, farmers use prophylactic antiprotozoal coccidiostats in feed, which increases the chance that coccidiostat residues are retained in both poultry meat and eggs. “To reduce the risk of toxicity to consumers, regulatory authorities have set maximum residue limits (MRLs) recommending an appropriate withdrawal period prior to slaughter,” Randox said.
Randox senior customer support scientist Mariclare McGarrity explained: “The key issue is the range of coccidiostat drugs utilised in the poultry industry. This leaves traditional single-analyte screening ELISA products unsuitable and inefficient. Producers are more likely to utilise confirmatory testing. However, Randox’s ground-breaking Biochip Array Technology is optimised for multiplex testing, identifying up to 22 different analytes from a single sample. As a result, it is an ideal platform to detect and quantify the whole range of commonly-used coccidiostats throughout the global market.”